Whalesbook
Innovation ka naya daur shuru!
Bernstein ki latest report ke mutabik, India ka pharma sector ek bade badlav se guzar raha hai. Ab sirf purane models pe nahi chalenge, balki innovation se earnings badhane ki koshish karenge. Brokerage ne cheh companies ko cover karna shuru kiya hai, jo investors ke liye ek naya direction sign kar raha hai. Yeh bada shift cheh high-growth segments se chalega: 505(b)(2) new drug applications, orphan indications, drug-device combinations, niche therapy drug repurposing, metabolic peptides, aur RNA/cellular therapies jisme CAR T-cell treatments bhi shamil hain. Analysts ka anuman hai ki yeh specialized areas agle das saal mein sector ki valuation ko $70 billion se $75 billion tak badha sakte hain, jisse sector ki total value $195 billion tak pahunch sakti hai.
Valuation aur Sector ka haal chaal
Filhaal, Indian pharma industry ka P/E ratio lagbhag 38.90 hai, jo ki iske 3-saal ke average 36.5x se thoda upar hai. Bernstein maanta hai ki kuch stocks ki valuation unki intrinsic value se kam hai, halanki Indian biopharma ki valuations apne long-term averages se aage nikal gayi hain. Unki report ke hisaab se, market pricing abhi domestic growth aur US generic pricing pressures ko reflect kar raha hai, lekin innovation aur emerging markets se hone wali growth ko poori tarah se nahi. Sector ne overall positive performance dikhaya hai, jismein 18 mein se 12 pharma stocks ne haal hi mein positive results diye hain.
Kaunsa stock kaisa perform karega?
Bernstein ne Zydus Lifesciences (P/E: ~20.70), Lupin (P/E: ~19.49-22.85), aur Sun Pharmaceutical Industries (P/E: ~34.72-41.52) ko 'Outperform' rating di hai. Zydus Lifesciences unki top pick hai. Iske vipareet, Biocon (P/E: ~150.76-190.28) aur Mankind Pharma (P/E: ~53.90-58.51) ko 'Underperform' mila hai. Aurobindo Pharma (P/E: ~23.04-25.81) ko 'Market-Perform' rating mili hai. Biocon aur Mankind Pharma ka valuation kaafi alag hai, jismein Biocon ka P/E industry median se bahut upar hai aur Mankind Pharma ka P/E bhi industry average 22.01 ke muqable kaafi high hai.
AI aur Quality se margin kaise badhega?
Artificial Intelligence (AI) ka use aur manufacturing quality par focus margin badhane mein aham role nibhayege. Bernstein ke models ke hisaab se, generative AI agle das saal mein profit margins ko 3 se 4% tak badha sakta hai, jismein R&D aur operations ka bada yogdaan rahega. Zydus aur Lupin isse sabse zyada fayda uthane wale hain. Firm ko lagta hai ki quality par focus se innovative medicines ka export badhega aur India future-ready biopharmaceutical manufacturing mein global leader ban sakta hai. Haalanki, import alerts aur regulatory challenges jaise purane mudde abhi bhi sector ke liye focus area hain.